• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Ribone 35
    / Unipharm

    Active Ingredient

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    4 X 35 mg

    partial basket chart 31859 18460

    Related information


    One tablet weekly.
    See prescribing information for full details.

    recommended drugs


    Treatment of postmenopausal osteoporosis, to reduce the risk of vertebral fractures. Treatment of established postmenopausal osteoporosis, to reduce the risk of hip fractures. Prevention of osteoporosis in postmenopausal women with increased risk of osteoporosis. Treatment of osteoporosis in men at high risk of fracture.


    Known hypersensitivity. Hypocalcemia, pregnancy and lactation, severe renal impairment.

    Special Precautions

    Efficacy in the treatment of postmenopausal osteoporosis is related to the presence of low bone mineral density and/or prevalent fracture. Evidence to support efficacy in very elderly women (>80 years) is limited). History of esophageal disorders which delay esophageal transit or emptying. Patients who are unable to stay in the upright position for at least 30 minutes after taking the tablet. Hypocalcemia should be treated before starting therapy. Other disturbances of bone and mineral metabolism (e.g. parathyroid dysfunction, hypovitaminosis D) should be treated at the same time as starting therapy.
    See prescribing information for full details.

    Side Effects

    Mild to moderate in severity and usually do not require cessation of therapy. Common reactions: Pain, dyspepsia, nausea, constipation, diarrhea, GI disorder, headache.
    See prescribing information for full details.

    Drug interactions

    medications containing polyvalent cations (e.g. calcium, magnesium, iron and aluminum).

    Trima Israel Pharmaceutical Products Maabarot Ltd. Israel